Molecular Partners Ag (MOLN) Retained Earnings (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Retained Earnings of $498254.0 for Q1 2026, up 16.05% year-on-year from $429347.6 in Q1 2025, and up 2.33% on a QoQ basis from $486929.0 in Q4 2025.
Molecular Partners Ag (MOLN) Retained Earnings (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Retained Earnings for 7 consecutive years, with $498254.0 the latest figure, recorded in Q1 2026.
- Quarterly Retained Earnings rose 16.05% year-over-year to $498254.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $498254.0 (up 16.05% YoY) and the FY2025 annual result came in at $486929.0, down 99.89% from the prior year.
- Retained Earnings improved to $498254.0 in Q1 2026 per MOLN's latest filing, from $486929.0 in the prior quarter.
- Over the last five years, Retained Earnings for MOLN reached as high as $439.3 million in Q4 2024 and fell as low as $371922.6 in Q3 2022.
- A 5-year average of $141.9 million and a median of $485303.8 in 2025 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2025 — Retained Earnings slumped 99.89% — and 2026, when it increased 16.05%.
- Year by year, Retained Earnings stood at $374.0 million in 2022, then rose by 10.18% to $412.1 million in 2023, then advanced by 6.62% to $439.3 million in 2024, then sank by 99.89% to $486929.0 in 2025, then advanced by 2.33% to $498254.0 in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered $498254.0, $486929.0, and $485303.8 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -27.89 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 12.91 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 115.82 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -622,000.00 |
| 10 | Molecular Partners Ag | 147.97 Mn | 147.97 Mn | - | 498,254.02 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 498,254.02 |
| Dec 31, 2025 | 486,929.01 |
| Sep 30, 2025 | 485,303.76 |
| Jun 30, 2025 | 467,615.38 |
| Mar 31, 2025 | 429,347.62 |
| Dec 31, 2024 | 439.34 Mn |
| Sep 30, 2024 | 425,415.40 |
| Jun 30, 2024 | 406.40 Mn |
| Mar 31, 2024 | 419,759.67 |
| Dec 31, 2023 | 412.08 Mn |
| Sep 30, 2023 | 412,538.28 |
| Jun 30, 2023 | 404.14 Mn |
| Mar 31, 2023 | 391,456.53 |
| Dec 31, 2022 | 374.02 Mn |
| Sep 30, 2022 | 371,922.56 |
| Jun 30, 2022 | 371.82 Mn |
| Mar 31, 2022 | 386,108.89 |
| Dec 31, 2021 | 385.01 Mn |
| Sep 30, 2021 | 385,235.86 |
| Dec 31, 2020 | 331.27 Mn |